Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1-2 Dose-escalation and Expansion Study of ST316 in Subjects With Selected Advanced Unresectable and Metastatic Solid Tumors

Next Previous
Trial Profile

A Phase 1-2 Dose-escalation and Expansion Study of ST316 in Subjects With Selected Advanced Unresectable and Metastatic Solid Tumors

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 14 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ST 316 (Primary)
  • Indications Adenocarcinoma; Advanced breast cancer; Cervical cancer; Cholangiocarcinoma; Colorectal cancer; Male breast cancer; Malignant melanoma; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Solid tumours; Synovial sarcoma; Triple negative breast cancer
  • Focus Adverse reactions; First in man; Proof of concept
  • Sponsors Sapience Therapeutics

Most Recent Events

  • 27 Jan 2025 According to a Sapience Therapeutics media release, company presented Phase 1 safety and biomarker data on ST316 at the 2025 American Society of Clinical Oncology (ASCO) Gastrointestinal (GI) Cancers Symposium.
  • 27 Jan 2025 Results consisting safety and biomarker data presented in the Sapience Therapeutics Media Release.
  • 08 Oct 2024 According to a Sapience Therapeutics media release, Company will present data from this study at the Society for Immunotherapy of Cancers (SITC) 39th Annual Meeting, being held Friday, November 9, 2024, in Houston, TX.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top